This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rea, D. Articles by Parker, M. G. Search for Related Content PubMed PubMed Citation Articles by Rea, D. Articles by Parker, M. G.

Effects of an Exon 5 Variant of the Estrogen Receptor in MCF-7 Breast Cancer Cells¹

Molecular Endocrinology Laboratory, Imperial Cancer Research Fund. 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom

The estrogen receptor gene gives rise to variant mRNAs, generated by alternative mRNA splicing, as well as the full-length mRNA containing eight coding exons. It has been postulated that one of these, the exon 5 variant, may be important in the development of hormone-independent and anti-estrogen-resistant breast cancer since it has the potential to encode a truncated receptor that retains the N-terminal activation domain AF-1, but lacks the hormone-binding domain. We have expressed the variant using an inducible promoter in estrogen receptor-positive MCF-7 cells and analyzed the effect of the variant protein on gene expression and cell growth. Inducible expression was validated using a specific antiserum that recognized a novel epitope on the exon 5 variant. The variant was able to stimulate transcription of a reporter gene in transiently transfected chicken embryo fibroblasts in the absence of hormone but showed weak constitutive activity when it was stably expressed in MCF-7 cells. The variant had no effect on the expression of the estrogen target genes, pS2, and the progesterone receptor. Finally, we analyzed whether the proliferation of MCF-7 cells was altered by the expression of the exon 5 variant and found that the stimulatory effects of estrogen and growth inhibitory effects of tamoxifen and ICI 182780 were unchanged. We therefore conclude that expression of the variant alone is not sufficient to give rise to hormone independence or tamoxifen resistance of breast cancers.

¹ This work was supported in part by Ciba-Geigy AG (Basel, Switzerland).

² To whom requests for reprints should be addressed.

Received 11/13/95. Accepted 1/30/96.

This article has been cited by other articles:

				W. Bryant, A. E. Snowhite, L. W. Rice, and M. A. Shupnik The Estrogen Receptor (ER){alpha} Variant {Delta}5 Exhibits Dominant Positive Activity on ER-Regulated Promoters in Endometrial Carcinoma Cells Endocrinology, February 1, 2005; 146(2): 751 - 759. [Abstract] [Full Text] [PDF]

				M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]

				H. A. LaVoie, D. C. DeSimone, C. Gillio-Meina, and Y. Y. Hui Cloning and Characterization of Porcine Ovarian Estrogen Receptor {beta} Isoforms Biol Reprod, March 1, 2002; 66(3): 616 - 623. [Abstract] [Full Text] [PDF]

				A. Bollig and R. J. Miksicek An Estrogen Receptor-{alpha} Splicing Variant Mediates Both Positive and Negative Effects on Gene Transcription Mol. Endocrinol., May 1, 2000; 14(5): 634 - 649. [Abstract] [Full Text]

				C. Pasqualini, D. Guivarc’h, Y. v. Boxberg, F. Nothias, J.-D. Vincent, and P. Vernier Stage- and Region-Specific Expression of Estrogen Receptor {alpha} Isoforms during Ontogeny of the Pituitary Gland Endocrinology, June 1, 1999; 140(6): 2781 - 2789. [Abstract] [Full Text]

				R. L. Balleine, S. M. N. Hunt, and C. L. Clarke Coexpression of Alternatively Spliced Estrogen and Progesterone Receptor Transcripts in Human Breast Cancer J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1370 - 1377. [Abstract] [Full Text]

				S. S. Chaidarun and J. M. Alexander A Tumor-Specific Truncated Estrogen Receptor Splice Variant Enhances Estrogen-Stimulated Gene Expression Mol. Endocrinol., September 1, 1998; 12(9): 1355 - 1366. [Abstract] [Full Text]

				I. Erenburg, B. Schachter, R. M. y Lopez, and L. Ossowski Loss of an Estrogen Receptor Isoform (ER{alpha}{Delta}3) in Breast Cancer and the Consequences of Its Reexpression: Interference with Estrogen-Stimulated Properties of Malignant Transformation Mol. Endocrinol., December 1, 1997; 11(13): 2004 - 2015. [Abstract] [Full Text] [PDF]